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Research on Aldo-keto reductases (AKRs) over the years has
revealed a remarkable diversity in the reactivity of these solu-
ble NAD(P)(H) oxidoreductases. The AKR enzymes primarily
catalyze the reduction of aldehydes and ketones to primary and
secondary alcohols, respectively. The 10 known human AKR
enzymes can turnover a vast range of endogenous and exogenous
substrates, including glucose, steroids, carcinogens, reactive alde-
hydes, and a variety of carbonyl-containing drugs. These enzymes
have been implicated in a number of human diseases, including
cancer and disorders of endocrinology and metabolism. AKRs
are involved in the development and progression of many can-
cers, as well as chemotherapeutic drug resistance. AKR1B1 and
AKR1B10 are overexpressed in tumors, such as liver, breast, and
lung cancer. Several AKRs (AKR1A1, AKR1B10, and AKR1C1-
3) are involved in tobacco-carcinogenesis, but they also catalyze
the detoxication of nicotine derived nitrosamino ketones. In addi-
tion, AKR1C1-3 enzymes play a key role in the regulation of
proliferative signaling in hormone dependent cancers. AKR1B1
has long been known for its involvement in diabetic complica-
tions. Recent studies now suggest AKR1B enzymes play a key role
in inflammatory diseases such as atherosclerosis, sepsis, asthma,
uveitis, and colon cancer by mediating oxidative stress-induced
inflammatory signals. In recognition of the role of AKR in var-
ious diseases, significant efforts have been made in the develop-
ment of specific/selective AKR1B1 and AKR1C3 inhibitors. The
aim of this Research Topic forum is to celebrate the advance-
ments seen in the AKR field via review papers and original
articles, as well as to promote future research in understand-
ing the underlying mechanism(s) of the role of AKRs in human
disease.
Eight review articles are included in this issue, and are
grouped into disease areas (cancer, disorders of endrocrinology
and metabolism) after the artile written by Chen and Zhang
(2012) which describes the current understanding of the regu-
lation of all human AKR members in relation to disease. The
significance of the AKR enzymes for research in various can-
cers is discussed in four review articles. The article by Matsunaga
et al. (2012) focuses on the role AKR1B10 in drug resistance
of cancer cells and the development of AKR1B10 inhibitors to
reverse chemoresistance. The article by Ruiz et al. (2012) describes
the retinaldehyde reductase activity of AKRs in relation to prolif-
eration and tumorigenesis. The paper from the Penning group
(Zhang et al., 2012) summarizes the role of AKR in the metabolic
activation and detoxication of polycyclic aromatic hydrocarbons
and the relevance of phase II conjugation reactions to human lung
carcinogenesis. Rižner (2012) provides a review on the role played
by AKR1B and AKR1C members in the pathogenesis of endome-
trial and cervical cancers, as well as other uterine diseases. The
aspect that members of AKRs can mediate the timing of partu-
rition through metabolism of progesterone and prostaglandins is
discussed by Byrns (2012). The role of AKR1B members in mod-
ification and production of signaling molecules is emphasized
by Pastel et al. (2012) for a better understanding of the phys-
iological and pathological role of AKR1B enzymes. The article
by Tang et al. (2012) focuses on the increases in oxidative stress
by AKR1B1 in pathogenesis of diabetic complications such as
cardiovascular diseases.
Three Original Research Articles follow the review articles. The
article by Fortier and coworkers (Bresson et al., 2012) reports
on the prostaglandin F synthase activity of AKR1B1 in differ-
ent models of living cells and tissues. This activity of AKR1B1
represents a novel target to regulate ischemic and inflammatory
responses associated with several human pathologic conditions.
The article by Laffin and Petrash (2012) examines the expression
of AKR1B1 and AKR1B10 across all major human cancer types.
Their findings point to the great potential of AKR1B1 inhibition
as novel cancer therapeutics. Schulze et al. (2012) describe their
studies on basal and regulatory promoter of AKR1C3 in relation
to prostate cancer.
As pointed out in the review article by Pastel et al. (2012) there
is a “marked contrast between the abundance of enzymatic data
and the small number of reports dedicated to functional studies
in a physiological context.” It is my hope that with an empha-
sis on the role of AKRs in human disease the articles included in
this issue will benefit a broad audience and the researchers in the
rapidly growing AKR filed.
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